what does the earlier application of immune-oncology agents mean for urological cancer teams?
Published 7 years ago • 51 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
4:00
overview of urothelial carcinoma treatment landscape – the promise of immunotherapy
-
2:03
the evolution of bladder cancer treatment and the immuno-oncology era
-
10:44
earlier use of immune checkpoint inhibitors to adjuvant and non muscle invasive bladder cancer
-
3:31
the use of immunotherapy as a first-line therapy for bladder cancer
-
7:32
the promise of immunotherapy in bladder cancer
-
2:01
using checkpoint inhibitors at earlier stages of bladder cancer – the next step in immunotherapy?
-
2:01
immune checkpoint inhibitors in urothelial bladder cancer
-
30:23
lecture looking ahead - potential barriers to immune checkpoint inhibitors use in mibc
-
10:46
cancer immunotherapy workshop 2021 – introduction to imaging applications in immuno-oncology
-
44:28
breakthroughs in bladder cancer immunotherapy, with matthew galsky
-
0:44
role of immunotherapy in bladder cancer
-
1:26:01
advancing the application of immuno-oncology to improve patient care
-
26:56
bladder cancer immunotherapy: building on a history of immune response
-
1:03:29
rcc: current applications, controversies, and future use of immunotherapy and targeted agents
-
55:15
2.22.2021 urology covid didactics - immunotherapy for bladder cancer
-
2:57
when can checkpoint inhibitors be used to treat urothelial carcinoma?
-
1:29:21
the central role of biomarker testing in piecing together the immuno-oncology puzzle
-
58:57
navigating the complexities of biomarker testing in the expanding field of precision immuno-oncology
-
1:09
teamwork between urologists and oncologists in the uk